Abstract:PURPOSE To determine the appropriate patients, methods, and timing for screening for diabetic retinopathy. DATA SOURCES Relevant articles were identified through prominent review articles, the authors' files, recommendations from experts, and a MEDLINE search (1986 to the present); additional references were selected from the bibliographies of identified articles. STUDY SELECTION Selection of articles on the natural history of retinopathy was limited to large clinical series and formal epidemiologic studies of defined populations. Selection of articles on the therapeutic effect of photocoagulation and of glycemic control was limited to randomized trials. Sources bearing on the accuracy of screening modalities were necessarily more varied. DATA EXTRACTION For important variables, individual estimates from multiple studies are presented rather than a single meta-analytic summary estimate. RESULTS Screening for retinopathy is justifiable if early detection leads to less vision loss at an acceptable cost. The evidence shows that 1) laser therapy reduces the rate of vision loss by 50% among patients with proliferative retinopathy and macular edema, conditions that are often asymptomatic; 2) duration of diabetes is the main risk factor for retinopathy; and 3) standard ophthalmoscopic examination has only moderate sensitivity (about 80% in research settings) and specificity (greater than 90% for proliferative retinopathy but lower for macular edema), making seven-field stereophotography a more accurate method. Estimates of cost effectiveness indicate that screening for retinopathy not only saves years of vision but may be cost saving from a societal perspective. CONCLUSIONS Screening for retinopathy in patients with diabetes, and subsequent photocoagulation therapy for those who have high risk macular edema or proliferative retinopathy, is clearly beneficial.

A Novel Mutation in Aspartoacylase Gene; Canavan Disease

Novel mutation in an Egyptian patient with infantile Canavan disease

A novel Aspartoacylase (ASPA) Gene Mutation in Canavan Disease

A Novel Disease-Causing ASPA Gene Mutation (c.432+1 G>C) in an Iranian Patient with Canavan Disease: A Case Report

Two patients with Canavan disease and structural modeling of a novel mutation

[A retrospective evaluation of exposure to dichloromethane by using a job-exposure matrix].

Canavan disease: Clinical features and recent advances in research

Canavan disease: A first case from Jordan

Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity

Clinical and Aspartoacylase Gene Mutation Analysis of Canavan Disease in a Child

The pathogenesis of, and pharmacological treatment for, Canavan disease

Comparative computational assessment of the pathogenicity of mutations in the Aspartoacylase enzyme

Cellular and molecular mechanisms of aspartoacylase and its role in Canavan disease

Canavan Disease - A Rare Case Report

Analysis of Aspartoacylase Gene Mutations in One Chinese Family with Canavan Disease

Evolutionarily conserved chaperone-mediated proteasomal degradation of a disease-linked aspartoacylase variant

The effect of ordering of internal water in thaumatin and lysozyme crystals as revealed by Raman method

Preimplantation Genetic Diagnosis of Canavan Disease

A missense mutation (p.G274R) in gene ASPA causes Canavan disease in a Pakistani family

Screening for Diabetic Retinopathy

A Novel Mutation of LRSAM1 in a Chinese Family with Charcot-Marie-Tooth Disease